Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study.
Chung CH, Bonomi M, Steuer CE, Li J, Bhateja P, Johnson M, Masannat J, Song F, Hernandez-Prera JC, Wenig BM, Molina H, Farinhas JM, McMullen CP, Wadsworth JT, Patel KB, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF.
Chung CH, et al. Among authors: steuer ce.
Cancers (Basel). 2021 Mar 9;13(5):1180. doi: 10.3390/cancers13051180.
Cancers (Basel). 2021.
PMID: 33803335
Free PMC article.